Peptide profile
FOXO4-DRI
Senolytic peptide for cellular rejuvenation
Compare FOXO4-DRI with other peptides →Summary
A tiny protein that clears out old, broken-down cells.
- Typical dose
- 1-5mg Once weekly
- Route
- Subcutaneous
- Cycle length
- 4-8 weeks
- Evidence
- Anecdotal
Mechanism
How it works
FOXO4-DRI works like a targeted demolition crew — it identifies weakened 'zombie' cells and safely removes them without damaging healthy neighbors.
FOXO4-DRI is a D-retro inverso peptide that disrupts FOXO4-p53 interaction, triggering apoptosis selectively in senescent cells.
Reported in research
Benefits
- Picks out and removes old 'zombie' cells
- Helps body parts work better in older animals
- Helps the kidneys and liver stay healthier
- Might help turn back some signs of aging
Context, not a prescription
Dosing
- Typical range
- 1-5mg Once weekly (Subcutaneous)
- Cycle length
- 4-8 weeks
Safety
Side effects & contraindications
Possible side effects
- Injection site inflammation
- Mild flu-like symptoms
- Temporary fatigue
- Severe immune reaction
- Excessive tissue healing
- Unknown long-term effects
Contraindications
- Pregnancy or breastfeeding
- Active infection or illness
- Autoimmune disease
- Recent major surgery
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Fewer old 'zombie' cells, body parts that heal better, and less long-lasting swelling.
How it works
FOXO4-DRI works like a careful cleanup crew. It finds the weak 'zombie' cells and clears them out. It leaves the healthy cells alone.
It grabs onto the FOXO4 protein and pushes p53 away. This tells only the old 'zombie' cells to shut down.
What to expect
It clears old cells in a few days. Body parts get better over a few weeks.
- Days 1-3: Your body's defense system wakes up. You might feel tired.
- Weeks 1-2: Slowly, long-lasting swelling and soreness go down.
- Weeks 4-8: Body parts start working better.
Good to know
- Begin with a very small amount (0.5mg)
- Use only for short times (4 weeks at most)
- Watch out for too much swelling
- Use only in science studies
Staying safe
- Swelling where you got the shot
- Feeling a little like you have a cold
- Feeling tired for a short time
Avoid if you have:
- If you are pregnant or breastfeeding
- If you are sick or have an infection
- If your body's defenses attack itself
- If you just had a big surgery
Mechanism of action
FOXO4-DRI is a D-retro inverso peptide that disrupts FOXO4-p53 interaction, triggering apoptosis selectively in senescent cells.
Binds to FOXO4 protein, displacing p53 and activating pro-apoptotic pathways only in senescent cells.
Pharmacodynamics
Senescent cell clearance within days; tissue improvements over weeks.
Reduced senescent cell burden, improved tissue regeneration, reduced chronic inflammation.
Timeline
- Days 1-3: Initial immune activation; possible fatigue.
- Weeks 1-2: Gradual reduction in chronic inflammation.
- Weeks 4-8: Tissue function improvements.
Comparisons
- FOXO4-DRI — effectiveness Emerging, safety Unknown, cost $$$, High to use
- Dasatinib + Quercetin — effectiveness Moderate, safety Good, cost $, Easy to use
Adverse effects
Common:
- Injection site inflammation
- Mild flu-like symptoms
- Temporary fatigue
Rare:
- Severe immune reaction
- Excessive tissue healing
- Unknown long-term effects
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Active infection or illness
- Autoimmune disease
- Recent major surgery
- Start with very low dose (0.5mg)
- Short cycles only (4 weeks max)
- Monitor for excessive inflammation
- Only in research settings
Qué hace
Menos células 'zombi' viejas, órganos que sanan mejor y menos inflamación duradera.
Cómo funciona
FOXO4-DRI funciona como un equipo de limpieza cuidadoso. Encuentra las células 'zombi' débiles y las elimina. Deja intactas a las células sanas.
Se agarra a la proteína FOXO4 y empuja a p53. Esto le indica solo a las células 'zombi' viejas que dejen de funcionar.
Qué esperar
Elimina las células viejas en unos días. Los órganos mejoran en unas semanas.
- Días 1-3: El sistema de defensa del cuerpo se activa. Podrías sentirte cansado.
- Semanas 1-2: Lentamente, la inflamación y el dolor duraderos disminuyen.
- Semanas 4-8: Los órganos comienzan a funcionar mejor.
Bueno saber
- Comenzar con una cantidad muy pequeña (0,5 mg)
- Usar solo por periodos cortos (máximo 4 semanas)
- Vigilar si hay demasiada hinchazón
- Usar solo en estudios científicos
Manteniéndose seguro
- Hinchazón en el lugar de la inyección
- Sentirse un poco resfriado
- Sentirse cansado por un corto tiempo
Evitar si tienes:
- Si estás embarazada o en periodo de lactancia
- Si estás enfermo o tienes una infección
- Si tus defensas atacan al propio cuerpo
- Si acabas de someterte a una cirugía mayor
Mecanismo de acción
FOXO4-DRI es un péptido D-retro inverso que interrumpe la interacción FOXO4-p53, desencadenando apoptosis selectiva en células senescentes.
Se une a la proteína FOXO4, desplazando a p53 y activando vías proapoptóticas únicamente en células senescentes.
Farmacodinamia
Eliminación de células senescentes en días; mejoras tisulares en semanas.
Reducción de la carga de células senescentes, mejora de la regeneración tisular, reducción de la inflamación crónica.
Cronología
- Días 1-3: Activación inmune inicial; posible fatiga.
- Semanas 1-2: Reducción gradual de la inflamación crónica.
- Semanas 4-8: Mejoras en la función tisular.
Comparaciones
- FOXO4-DRI — efectividad Emergente, seguridad Desconocida, costo $$$, Alta de usar
- Dasatinib + Quercetina — efectividad Moderada, seguridad Buena, costo $, Fácil de usar
Efectos adversos
Comunes:
- Inflamación en el sitio de inyección
- Síntomas leves similares a la gripe
- Fatiga temporal
Raros:
- Reacción inmune severa
- Cicatrización tisular excesiva
- Efectos a largo plazo desconocidos
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Infección o enfermedad activa
- Enfermedad autoinmune
- Cirugía mayor reciente
- Comenzar con dosis muy baja (0,5 mg)
- Solo ciclos cortos (máximo 4 semanas)
- Vigilar inflamación excesiva
- Solo en entornos de investigación
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 4-8 weeks
FAQ
Common questions
Is FOXO4-DRI proven in humans?
No, only animal studies (mice) show rejuvenation effects. No human trials exist.
What are the risks?
Unknown long-term risks. Potential for excessive tissue remodeling or immune reactions.
What is the evidence level?
This compound is classified as Anecdotal. Evidence relies primarily on self-reported user experiences. Controlled studies are lacking.
Research
Research & sources
Current evidence for FOXO4-DRI is rated as Anecdotal. No controlled clinical research is available.
- 1. FOXO4-DRI in aged mice (2017) — DOI:10.1016/j.cell.2017.03.048
- 2. Senolytics review (2018) — DOI:10.1038/s41591-018-0225-0
- 3. FOXO4-DRI in aged mice (2017)
- 4. Senolytics review (2018)